Engineered anti-TSLP antibody
View Patent ↗The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
1. A method of suppressing a Th2-mediated immune response in a human subject comprising administering to a subject in need thereof an isolated antibody that specifically binds human and cyno TSLP, or a TSLP-binding fragment thereof, in an amount effective to block the biological activity of TSLP; wherein the antibody is selected from the group consisting of:
(i) an antibody comprising the three CDR sequences set forth in SEQ ID NOs: 1, 2 and 3 and the three CDR sequences set forth in SEQ ID NOs: 4, 5 and 6;
(ii) a monoclonal antibody that specifically binds to the epitope on human TSLP that is bound by the antibody produced by the hybridoma deposited as PTA-7951; and
(iii) a monoclonal antibody that competitively inhibits binding by the antibody produced by the hybridoma deposited as PTA-7951 to human TSLP.
2. The method of claim 1 , wherein the immune response is an allergic inflammatory disorder.
3. The method of claim 2 , wherein the subject has atopic dermatitis.
4. The method of claim 2 , wherein the subject has a disorder selected from the group consisting of allergic rhinosinusitis, allergic asthma, allergic conjunctivitis, or asthma.